NDAORALCAPSULE1 Generic Approved
Approved
Sep 2013
Lifecycle
Peak
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
5/8 — Partial
CYCLOPHOSPHAMIDE (cyclophosphamide) by Hikma is alkylating activity [moa]. Approved for breast cancer, acute lymphoblastic leukemia, lymphoma and 1 more indications. First approved in 2013.
Drug data last refreshed 20h ago
Mechanism of Action
Alkylating Activity
Indications (4)
Worked on CYCLOPHOSPHAMIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.